MedTrace Logo

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

NCT00897702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 269

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working. However, we do not know if the same molecules change in patients. This study is being done to see if they do change. If we learn more about how patients become resistant, we may be able to offer better treatment in the future.

Conditions

Interventions

OTHER

Blood draw

A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.

OTHER

immunoenzyme technique

PROCEDURE

biopsy

PROCEDURE

histopathologic examination

Sponsors & Collaborators

Principal Investigators

  • Sarat Chandarlapaty, MD, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-09
Primary Completion
2026-01-23
Completion
2026-01-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897702 on ClinicalTrials.gov